ARIUS Research Licenses Antibody to Genentech

24-Mar-2006

ARIUS Research Inc. announced that it has licensed to Genentech, Inc. rights to one of ARIUS' novel anti-cancer antibodies and others in the same family for development in human disease. Under the terms of the agreement, ARIUS will receive an upfront licensing fee and may receive milestone payments based on progress through clinical development as well as royalties on net sales of any products resulting from the collaboration. Genentech will assume the responsibility and costs of development and commercialization. Financial terms were not disclosed.

Other news from the department research and development

More news from our other portals

All FT-IR spectrometer manufacturers at a glance

See the theme worlds for related content

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world
Topic world Antibodies

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous